ReP USP - Resultado da busca

Artigo de periodico
Enhanced elimination of betamethasone in dichorionic twin pregnancies (2022)
Rodrigues, Grazielle de Fátima Pinto ; Benzi, Jhohann Richard de Lima ; Matos, Luísa Helena de Castro; Freitas, Stella Felippe de; Marques, Maria Paula ; Cavalli, Ricardo de Carvalho; Moisés, Elaine Christine Dantas ; Duarte, Geraldo; Lanchote, Vera Lucia ; Marcolin, Alessandra Cristina
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: GRAVIDEZ, FARMACOCINÉTICA, PLACENTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Grazielle de Fátima Pinto et al. Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, v. 88, n. 4, p. 1897-1903, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15111. Acesso em: 16 nov. 2024.
APA
Rodrigues, G. de F. P., Benzi, J. R. de L., Matos, L. H. de C., Freitas, S. F. de, Marques, M. P., Cavalli, R. de C., et al. (2022). Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, 88( 4), 1897-1903. doi:10.1111/bcp.15111
NLM
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.15111
Vancouver
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.15111
Artigo de periodico
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli (2022)
Abichabki, Nathália de Lima Martins ; Zacharias, Luísa Vieira; Moreira, Natália Columbaro; Bellíssimo-Rodrigues, Fernando; Moreira, Fernanda L.; Benzi, Jhohann Richard de Lima ; Ogasawara, Tânia Mara Casare; Ferreira, Joseane Cristina; Ribeiro, Camila M.; Pavan, Fernando R.; Pereira, Leonardo Régis Leira; Brancini, Guilherme Thomaz Pereira; Braga, Gilberto Ubida Leite; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Lanchote, Vera Lucia ; Cantón, Rafael; Darini, Ana Lúcia da Costa ; Andrade, Leonardo Neves de
Source: Scientific Reports. Unidades: FMRP, FCFRP
Subjects: CANABINOIDES, REPOSICIONAMENTO DE FÁRMACOS, RESISTÊNCIA MICROBIANA ÀS DROGAS, SINERGISMO DE DROGAS, TESTES DE SENSIBILIDADE MICROBIANA, BACTÉRIAS GRAM-NEGATIVAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ABICHABKI, Nathália de Lima Martins et al. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, v. 12, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-10393-8. Acesso em: 16 nov. 2024.
APA
Abichabki, N. de L. M., Zacharias, L. V., Moreira, N. C., Bellíssimo-Rodrigues, F., Moreira, F. L., Benzi, J. R. de L., et al. (2022). Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, 12, 1-15. doi:10.1038/s41598-022-10393-8
NLM
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Vancouver
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Artigo de periodico
Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale (2021)
Seixas-Moizes, Julieta; Boerlage, Anneke; Lia, Érica Negrini; Santos, Lucas Emmanuel Lopes e; Zucoloto, Miriane Lucindo; Dach, Fabíola; Papassidero, Priscila Colavite; Wichert-Ana, Laís Almeida Leal; Della Pasqua, Oscar; Wiesebron, Marianne Louise; Icuma, Tatiana Reis; Lanchote, Vera Lucia; Coelho, Eduardo Barbosa; Tibboel, Dick; Wichert-Ana, Lauro
Source: Dementia and Geriatric Cognitive Disorders Extra. Unidades: FMRP, FCFRP
Subjects: DOR, IDOSOS, ESTUDOS DE VALIDAÇÃO, DEMÊNCIA, ESTUDOS MULTICÊNTRICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SEIXAS-MOIZES, Julieta et al. Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale. Dementia and Geriatric Cognitive Disorders Extra, v. 11, n. 3, p. 314-323, 2021Tradução . . Disponível em: https://doi.org/10.1159/000520455. Acesso em: 16 nov. 2024.
APA
Seixas-Moizes, J., Boerlage, A., Lia, É. N., Santos, L. E. L. e, Zucoloto, M. L., Dach, F., et al. (2021). Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale. Dementia and Geriatric Cognitive Disorders Extra, 11( 3), 314-323. doi:10.1159/000520455
NLM
Seixas-Moizes J, Boerlage A, Lia ÉN, Santos LEL e, Zucoloto ML, Dach F, Papassidero PC, Wichert-Ana LAL, Della Pasqua O, Wiesebron ML, Icuma TR, Lanchote VL, Coelho EB, Tibboel D, Wichert-Ana L. Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale [Internet]. Dementia and Geriatric Cognitive Disorders Extra. 2021 ; 11( 3): 314-323.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1159/000520455
Vancouver
Seixas-Moizes J, Boerlage A, Lia ÉN, Santos LEL e, Zucoloto ML, Dach F, Papassidero PC, Wichert-Ana LAL, Della Pasqua O, Wiesebron ML, Icuma TR, Lanchote VL, Coelho EB, Tibboel D, Wichert-Ana L. Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale [Internet]. Dementia and Geriatric Cognitive Disorders Extra. 2021 ; 11( 3): 314-323.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1159/000520455
Artigo de periodico
Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor (2021)
Filgueira, Gabriela Campos de Oliveira; Rodrigues, Grazielle de Fátima Pinto; Benzi, Jhohann Richard de Lima ; Nardotto, Glauco Henrique Balthazar ; Marques, Maria Paula ; Lanchote, Vera Lucia ; Cavalli, Ricardo de Carvalho
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: TRABALHO DE PARTO INDUZIDO, PROSTAGLANDINAS SINTÉTICAS, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, GRAVIDEZ, HEMORRAGIA, PLACENTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FILGUEIRA, Gabriela Campos de Oliveira et al. Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor. Journal of Pharmaceutical and Biomedical Analysis, v. 202, p. 1-7, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2021.114138. Acesso em: 16 nov. 2024.
APA
Filgueira, G. C. de O., Rodrigues, G. de F. P., Benzi, J. R. de L., Nardotto, G. H. B., Marques, M. P., Lanchote, V. L., & Cavalli, R. de C. (2021). Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor. Journal of Pharmaceutical and Biomedical Analysis, 202, 1-7. doi:10.1016/j.jpba.2021.114138
NLM
Filgueira GC de O, Rodrigues G de FP, Benzi JR de L, Nardotto GHB, Marques MP, Lanchote VL, Cavalli R de C. Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2021 ; 202 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2021.114138
Vancouver
Filgueira GC de O, Rodrigues G de FP, Benzi JR de L, Nardotto GHB, Marques MP, Lanchote VL, Cavalli R de C. Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2021 ; 202 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2021.114138
Artigo de periodico
Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model (2021)
Pinto, Leonardo Santos Ribeiro; Bapat, Priya; Moreira, Fernanda de Lima; Lubetsky, Angelika; Cavalli, Ricardo de Carvalho; Berger, Howard; Lanchote, Vera Lucia ; Koren, Gideon
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTAGONISTAS, FARMACOTERAPIA, ANTIDEPRESSIVOS, PLACENTA, COMPLICAÇÕES NA GRAVIDEZ, ANTI-HISTAMÍNICOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, v. 38, n. 4, p. 647-655, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11095-021-03035-7. Acesso em: 16 nov. 2024.
APA
Pinto, L. S. R., Bapat, P., Moreira, F. de L., Lubetsky, A., Cavalli, R. de C., Berger, H., et al. (2021). Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, 38( 4), 647-655. doi:10.1007/s11095-021-03035-7
NLM
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Vancouver
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Artigo de periodico
Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics (2021)
Pippa, Leandro Francisco ; Pereira, Maria Paula Marques ; Silva, Anna Christina Tojal da; Vilar, Fernando Crivelenti; Haes, Tissiana Marques de; Fonseca, Benedito Antonio Lopes da; Martinez, Roberto ; Coelho, Eduardo Barbosa ; Wichert-Ana, Lauro; Lanchote, Vera Lucia
Source: Frontiers in Chemistry. Unidades: FCFRP, FMRP, EERP
Subjects: ANTIFÚNGICOS, LÍQUIDO CEFALORRAQUIDIANO, FARMACOCINÉTICA, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, v. 9, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.3389/fchem.2021.782131. Acesso em: 16 nov. 2024.
APA
Pippa, L. F., Pereira, M. P. M., Silva, A. C. T. da, Vilar, F. C., Haes, T. M. de, Fonseca, B. A. L. da, et al. (2021). Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, 9, 1-14. doi:10.3389/fchem.2021.782131
NLM
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Vancouver
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Artigo de periodico
Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
Tozatto, Eduardo; Benzi, Jhohann Richard de Lima ; Rocha, Adriana; Coelho, Eduardo Barbosa ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 16 nov. 2024.
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1745
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1745
Artigo de periodico
Clinical treatment for hepatitis C reverses CYP2C19 inhibition (2021)
Pippa, Leandro Francisco ; Vieira, Carolina Pinto; Caris, Juciene Aparecida; Rocha, Adriana; Garcia, Camile Prates; Rezende, Rosamar Eulira Fontes; Lanchote, Vera Lucia
Source: British Journal of Clinical Pharmacology. Unidade: FCFRP
Subjects: ANTIVIRAIS, CITOCROMO P-450, FLAVIVIRIDAE, HEPATITE C, HEPATITE CRÔNICA, FARMACOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, v. 87, n. 10, p. 4013-4019, 2021Tradução . . Disponível em: https://doi.org/10.1111/bcp.14829. Acesso em: 16 nov. 2024.
APA
Pippa, L. F., Vieira, C. P., Caris, J. A., Rocha, A., Garcia, C. P., Rezende, R. E. F., & Lanchote, V. L. (2021). Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, 87( 10), 4013-4019. doi:10.1111/bcp.14829
NLM
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.14829
Vancouver
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.14829
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 16 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio (2020)
Pippa, Leandro Francisco ; Oliveira, Milena Locci de ; Rocha, Adriana; Andrade, Jurandyr Moreira de ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOCINÉTICA, VARIAÇÃO (BIOLOGIA), NEOPLASIAS MAMÁRIAS, MIOCARDIOPATIA CONGESTIVA, QUIMIOTERAPIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113231. Acesso em: 16 nov. 2024.
APA
Pippa, L. F., Oliveira, M. L. de, Rocha, A., Andrade, J. M. de, & Lanchote, V. L. (2020). Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113231
NLM
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Vancouver
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Artigo de periodico
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia (2020)
Oliveira, Milena Locci de ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Pippa, Leandro Francisco ; Simões, Belinda Pinto ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, METABÓLITOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Milena Locci de et al. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, v. 191, p. 1-8, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113576. Acesso em: 16 nov. 2024.
APA
Oliveira, M. L. de, Rocha, A., Nardotto, G. H. B., Pippa, L. F., Simões, B. P., & Lanchote, V. L. (2020). Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, 191, 1-8. doi:10.1016/j.jpba.2020.113576
NLM
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Vancouver
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Artigo de periodico
Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers (2020)
Cestari, Roberta Natália ; Caris, Juciene Aparecida ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Oliveira, Renê Donizeti Ribeiro de; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ESTATINAS, FARMACOCINÉTICA, FARMACOLOGIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, COMPOSTOS ORGÂNICOS, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, v. 182, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113128. Acesso em: 16 nov. 2024.
APA
Cestari, R. N., Caris, J. A., Rocha, A., Nardotto, G. H. B., Oliveira, R. D. R. de, & Lanchote, V. L. (2020). Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 182, 1-7. doi:10.1016/j.jpba.2020.113128
NLM
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Vancouver
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Artigo de periodico-carta/editorial
Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] (2020)
Vieira, Carolina Pinto; Neves, Daniel Valente; Nardotto, Glauco Henrique Balthazar; Cesarino, Evandro José ; Rocha, Adriana; Zanardi, Ailton Marcelo Castilho Teno; Lanchote, Vera Lucia
Source: European Journal of Clinical Pharmacology. Unidade: FCFRP
Subjects: BETA-BLOQUEADORES, HIPERTENSÃO, METABOLISMO, IDOSOS, FARMACOCINÉTICA, DOENÇA DE CHAGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEIRA, Carolina Pinto et al. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1007/s00228-020-02837-9. Acesso em: 16 nov. 2024. , 2020
APA
Vieira, C. P., Neves, D. V., Nardotto, G. H. B., Cesarino, E. J., Rocha, A., Zanardi, A. M. C. T., & Lanchote, V. L. (2020). Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1007/s00228-020-02837-9
NLM
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s00228-020-02837-9
Vancouver
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s00228-020-02837-9
Artigo de periodico
A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: LÍQUIDO AMNIÓTICO, FÁRMACOS DIURÉTICOS, GRAVIDEZ, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ, CESÁREA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section. The Journal of Clinical Pharmacology, v. 60, n. 12, p. 1655-1661, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1681. Acesso em: 16 nov. 2024.
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Duarte, G., & Lanchote, V. L. (2020). A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section. The Journal of Clinical Pharmacology, 60( 12), 1655-1661. doi:10.1002/jcph.1681
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Duarte G, Lanchote VL. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 12): 1655-1661.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1681
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Duarte G, Lanchote VL. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 12): 1655-1661.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1681
Artigo de periodico
Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin (2020)
Cestari, Roberta Natália ; Oliveira, Renê Donizeti Ribeiro de; Souza, Flávio Falcão Lima de; Pippa, Leandro Francisco ; Nardotto, Glauco Henrique Balthazar ; Rocha, Adriana; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia
Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: LÚPUS ERITEMATOSO SISTÊMICO, FARMACOCINÉTICA, FÁRMACOS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin. Clinical and Translational Science, v. 13, n. 6, p. 1227-1235, 2020Tradução . . Disponível em: https://doi.org/10.1111/cts.12808. Acesso em: 16 nov. 2024.
APA
Cestari, R. N., Oliveira, R. D. R. de, Souza, F. F. L. de, Pippa, L. F., Nardotto, G. H. B., Rocha, A., et al. (2020). Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin. Clinical and Translational Science, 13( 6), 1227-1235. doi:10.1111/cts.12808
NLM
Cestari RN, Oliveira RDR de, Souza FFL de, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin [Internet]. Clinical and Translational Science. 2020 ; 13( 6): 1227-1235.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cts.12808
Vancouver
Cestari RN, Oliveira RDR de, Souza FFL de, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin [Internet]. Clinical and Translational Science. 2020 ; 13( 6): 1227-1235.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cts.12808
Artigo de periodico
Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics (2020)
Godoy, Ana Leonor Pardo Campos; Jesus, Clauceane de; Gonçalves, Rafaela S.; Azeredo, Francine Johansson; Rocha, Adriana; Marques, Maria Paula ; Lanchote, Vera Lucia ; Larangeira, Daniela Farias; Barrouin-Melo, Stella Maria
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidade: FCFRP
Subjects: ÁCIDO ÚRICO, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, CÃES, URINA, PARASITOLOGIA, LEISHMANIA INFANTUM, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GODOY, Ana Leonor Pardo Campos et al. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113204. Acesso em: 16 nov. 2024.
APA
Godoy, A. L. P. C., Jesus, C. de, Gonçalves, R. S., Azeredo, F. J., Rocha, A., Marques, M. P., et al. (2020). Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113204
NLM
Godoy ALPC, Jesus C de, Gonçalves RS, Azeredo FJ, Rocha A, Marques MP, Lanchote VL, Larangeira DF, Barrouin-Melo SM. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113204
Vancouver
Godoy ALPC, Jesus C de, Gonçalves RS, Azeredo FJ, Rocha A, Marques MP, Lanchote VL, Larangeira DF, Barrouin-Melo SM. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113204

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration